Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Stelara image

NICE U-turn on Janssen arthritis drug

June 4, 2015
Sales and Marketing Janssen, NICE, Stelara, psoriasis, uturn

NICE has performed a U-turn on Janssen’s Stelara and has now recommended the drug for the treatment of psoriatic arthritis. …

News
NICE image

NICE: people should be more involved in medical decisions

June 2, 2015
Sales and Marketing NHS, NICE, medicines, optimisation

Around 15 million people in England now have at least one long-term condition, but figures suggest that as many as …

News
Roche logo

NICE signs-off Roche’s Gazyvaro for leukaemia

June 2, 2015
Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia

NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …

News

NICE Lynparza rejection labelled ‘hard to understand’

June 2, 2015
Sales and Marketing AstraZeneca, NICE, lynparza, olaparib

AstraZeneca has appealed to the government to put ‘urgent transitional measures’ in place to make sure patients can access innovative …

News
novartis_window

NICE green-light for Novartis skin drug

May 29, 2015
Sales and Marketing Cosentyx, IL-17, NICE, Novartis, Secukinumab

NICE has released positive draft guidance for three treatments, including the first in a new generation of psoriasis drugs. Novartis’ …

News
NICE image

NICE sets out office for market access plans

May 28, 2015
Sales and Marketing ABPI, EMA, NHS, NICE, eams, market access

The UK healthcare watchdog NICE is to set up a new office for market access to advise pharma companies on …

News

Pharma accused of hiding behind regulation and undermining NICE

April 29, 2015
Medical Communications, Sales and Marketing NHS, NICE, Royal Society of Medicine, UK, brett wells, health, pharma

University of York health economists have argued that pharma regulation is not evidence-based, lacks accountability and undermines NICE. Writing in …

News
BMS image

BMS lifted by new products

April 28, 2015
Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C

New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …

News
Novartis image

Novartis heart drug steps closer to EAMS scheme

April 23, 2015
Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan

Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …

News
Amgen image

FDA approves Amgen’s heart failure drug

April 16, 2015
Sales and Marketing Amgen, Corlanor, FDA, NICE, Vectibix, heart, ivabradine

Amgen has earned sign-off from the FDA for Corlanor as a treatment for people with worsening heart failure symptoms. Corlanor …

News
arzerra image

Trial results back NICE decision on Novartis cancer drug

April 15, 2015
Sales and Marketing Arzerra, Cancer, NHS, NICE, chemo, chlorambucil, fludarabine, leukaemia, ofatumumab

Treatment with Arzerra improves survival in people with chronic lymphocytic leukaemia (CLL) according to study results that back NICE’s decision …

News
Market access means new drugs are available to prescribe to patients

Refining UK market access

April 7, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, UK, health, market access

“Some people have said NICE needs to change, it needs to create a new vision, but we say we need …

Feature
capture

NICE names new non-executive director

March 25, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, tim irish

The Department of Health has appointed Tim Irish as a non-executive director of the National Institute for Health and Care …

Appointment
Velcade image

J&J blood cancer drug gets UK launch

March 25, 2015
Sales and Marketing Cancer, J&J, JJ, Janssen, NICE, Velcade, bortezomib, mcl, nhl

Johnson and Johnson’s pharma unit Janssen is launching Velcade in the UK for the first-line treatment of Mantle Cell Lymphoma …

News
Sanofi image

Type 1 diabetes market value to double by 2023

March 19, 2015
Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1

The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026